Research Finds Lower Care Costs with Increased Use of New Drugs for Treatment of Pancreatic Cancer Patients

The results of a new study by Tyme Technologies, Inc., suggests the increased use of novel drugs in the treatment of pancreatic cancer is responsible for driving down total health care costs.

The data were set to be presented during the International Society for Pharmacoeconomics and Outcomes Research’s (ISPOR) virtual conference.

“Our study looked at treatment inflation-adjusted expenses per patient for pancreatic cancer care between 2009 and 2016 and found that for every additional $1 spent on medicines for pancreatic cancer in 2016, there was a reduction in non-drug spending of $8 – $9,” Center for Medicine in the Public Interest Co-Founder and Vice President Robert Goldberg said.

To read the full press release, click here.